DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note released on Sunday morning. The brokerage issued a hold rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. HC Wainwright boosted their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and set a $25.00 price target on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Trading Down 4.6 %

Shares of NASDAQ DBVT opened at $3.33 on Friday. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $10.70. The firm has a market capitalization of $68.50 million, a price-to-earnings ratio of -0.77 and a beta of 0.64. The firm has a 50 day moving average of $3.46 and a 200 day moving average of $4.06.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.